Korea Joongang Daily
Korea JoongAng Daily

Samsung Biologics to launch ADC drug product service in 2027

Samsung Biologics is preparing to launch an antibody-drug conjugate (ADC) drug product service in the first quarter of 2027, reflecting its efforts to more closely link drug development with downstream manufacturing.

2026-01-18

Samsung Biologics makes headway with its ADC business

Samsung Biologics is set to secure multiple deals for its new antibody-drug conjugate business at the J.P. Morgan Healthcare Conference.

2025-01-16

Samsung Biologics, LigaChem Biosciences expand cancer treatment collaboration

Samsung Biologics and Ligachem Biosciences will expand their collaboration on projects to develop antibody-drug conjucates used in cancer treatments.

2025-01-09

Samsung Life Science Fund invests in Massachusetts-based BrickBio

Samsung Biologics, Samsung Bioepis and Samsung C&T will work with the U.S. firm on next-generation cancer treatment with antibody-drug conjugates.

2024-03-19

[NEWS IN FOCUS] Watch out for 'biological missile drugs,' the next big thing in pharma

Antibody-drug conjugates (ADCs) are a growing trend in cancer treatment, with recent breakthroughs attracting significant investment from pharmaceutical and biotech companies worldwide.

2024-01-23

LegoChem Biosciences signs ADC deal with Iksuda Therapeutics

LegoChem Biosciences has signed a technology-transfer deal with Iksuda Therapeutics for antibody-drug conjugate (ADC) technology, the Kosdaq-listed company said Monday.

2021-12-27

LegoChem Biosciences signs deal with Prague's Sotio Biotech

LegoChem Biosciences has inked a technology transfer deal worth up to $1.03 billion with Sotio Biotech for antibody-drug conjugate (ADC) technology, the Kosdaq-listed company said Wednesday.

2021-11-17